Vabysmo: One Injection, Two Targets, Four Months Between Visits

The disease

Wet age-related macular degeneration (AMD) destroys central vision. Abnormal blood vessels grow behind the retina, leak fluid and blood, and damage the macula - the part of the retina responsible for sharp, central sight. Reading, driving, and recognizing faces become progressively harder. Without treatment, wet AMD leads to severe vision loss within months.

The driver is VEGF-A (vascular endothelial growth factor A). VEGF-A signals the body to grow new blood vessels. In the retina, excess VEGF-A triggers abnormal vessel growth - vessels that are fragile, leaky, and damaging.

The anti-VEGF era

In 2006, Genentech's Lucentis (ranibizumab) became the first anti-VEGF therapy approved specifically for wet AMD. It blocked VEGF-A with a monthly intravitreal injection - a needle inserted directly into the eye. Before Lucentis, there was no effective treatment for most wet AMD patients. The drug preserved and often improved vision.

Genentech's Avastin (bevacizumab), approved for colon cancer, was widely used off-label for wet AMD at a fraction of Lucentis's cost. In 2011, Regeneron's Eylea (aflibercept) arrived, blocking VEGF-A and the related proteins VEGF-B and PlGF, with dosing that could extend to every 8 weeks after initial monthly loading. US ophthalmologists now perform roughly 2.5 million anti-VEGF injections per year, costing Medicare $2.7 billion annually.

All of these drugs block the same pathway: VEGF-A. And all require repeated injections into the eye - monthly for some patients, every 8 weeks for others. For a disease that progresses over years to decades, this means years of regular clinic visits and intravitreal injections.

The second signal

VEGF-A drives new vessel growth. But there's a second signal involved in retinal vascular disease: Ang-2 (angiopoietin-2).

Blood vessels are normally stabilized by pericytes - cells that wrap around the vessel wall - and by a signaling system called the Ang-1/Tie2 axis. Ang-1 activates the Tie2 receptor on endothelial cells, promoting tight junctions and vascular stability.

Ang-2 disrupts this. It competes with Ang-1 for the Tie2 receptor but doesn't activate it the same way. Instead, Ang-2 destabilizes existing blood vessels - loosening cell junctions, reducing pericyte coverage, and making the vasculature more permeable and more responsive to VEGF-A. Ang-2 and VEGF-A work synergistically: Ang-2 primes the vessels for leakage and growth, and VEGF-A drives it. Blocking VEGF-A alone leaves the Ang-2-mediated destabilization unaddressed.

Two targets in one injection

Roche's Vabysmo (faricimab) is a bispecific antibody. One arm binds and neutralizes VEGF-A. The other arm binds and neutralizes Ang-2. A single intravitreal injection blocks both pathways simultaneously.

This is different from how Hemlibra uses its two arms (bridging two proteins together) or how T-cell engagers use theirs (forcing two cells together). Vabysmo's two arms are both blocking - dual pathway inhibition in one molecule.

The FDA approved Vabysmo in January 2022 for wet AMD and diabetic macular edema (DME), and later for retinal vein occlusion (RVO).

The interval data

The pivotal TENAYA and LUCERNE trials enrolled 1,329 treatment-naive wet AMD patients across 271 sites worldwide. Patients received either Vabysmo (dosed up to every 16 weeks based on disease activity) or Regeneron's Eylea (dosed every 8 weeks, the standard at the time).

Vabysmo matched Eylea's visual acuity improvements. The difference was in how often patients needed to come back. By year one, 45-46% of Vabysmo patients were on 16-week intervals - three injections a year instead of six or more. By year two, that number exceeded 60%. Another 33-34% were on 12-week intervals. Roughly 80% of patients were receiving injections every 12 weeks or longer.

For a treatment delivered by needle into the eye, reducing visits from monthly or bimonthly to every four months is a meaningful change. Each visit involves clinic time, dilation, the injection itself, and recovery. Many patients need someone to drive them. Some patients travel hours to reach a retinal specialist.

Want the next brief? Subscribe - free, every two weeks.

The revenue

Vabysmo launched in early 2022 and grew faster than any product in Roche's history.

The retinal market

The AMD drug market was valued at approximately $10.5 billion in 2024 and is projected to reach $17.4 billion by 2029. Two products are competing for the next decade.

Roche's Vabysmo offers dual-pathway blockade and extended dosing intervals. Regeneron's Eylea HD (aflibercept 8mg), approved in August 2023, is a higher-dose version of Eylea that also extends dosing intervals - up to every 12-16 weeks - but blocks only VEGF pathway targets (VEGF-A, VEGF-B, PlGF). Eylea HD generated $504 million in its first half of 2024 and is growing rapidly, particularly in treatment-naive patients.

Meanwhile, biosimilars for the original Eylea (aflibercept 2mg) are arriving. The FDA approved interchangeable Eylea biosimilars in May 2024. As the original Eylea faces biosimilar erosion, the retinal market is splitting: biosimilars competing on price for the standard formulation, while Vabysmo and Eylea HD compete on interval extension and clinical differentiation.

Roche and Regeneron are forecast to capture more than 60% of the retinal biologics sector by 2030. Vabysmo is the first bispecific antibody approved for the eye, and its dual-pathway approach opened a therapeutic area that was previously defined by single-target anti-VEGF drugs. The same concept - one molecule, two targets - applied here means something different than in hemophilia or oncology. Both arms block. Neither bridges or forces. The clinical consequence is measured in months between visits.